Known targets — ChEMBL curated mechanism
AKT1AKT2AKT3PRKACAPRKACBPRKACGPRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3
The experimentally established mechanism targets of Gsk-690693. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 known ✓ | P31749 | 19/20 | 1.00 |
| ▸ | AKT2 known ✓ | P31751 | 14/20 | 1.00 |
| ▸ | AKT3 known ✓ | Q9Y243 | 7/20 | 1.00 |
| ▸ | PRKD3 known ✓ | O94806 | 1/20 | 1.00 |
| ▸ | PRKCB known ✓ | P05771 | 1/20 | 1.00 |
| ▸ | PRKCA known ✓ | P17252 | 1/20 | 1.00 |
| ▸ | PRKACA known ✓ | P17612 | 1/20 | 1.00 |
| ▸ | PRKACB known ✓ | P22694 | 1/20 | 1.00 |
| ▸ | PRKCH known ✓ | P24723 | 1/20 | 1.00 |
| ▸ | PRKCI known ✓ | P41743 | 1/20 | 1.00 |
| ▸ | PRKCE known ✓ | Q02156 | 1/20 | 1.00 |
| ▸ | PRKCQ known ✓ | Q04759 | 1/20 | 1.00 |
| ▸ | PRKCD known ✓ | Q05655 | 1/20 | 1.00 |
| ▸ | PRKD1 known ✓ | Q15139 | 1/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 16/20 | 1.00 |
| ▸ | RPS6KA1 | Q15418 | 15/20 | 1.00 |
| ▸ | RPS6KA5 | O75582 | 7/20 | 1.00 |
| ▸ | GSK3B | P49841 | 4/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | DCLK1 | O15075 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk-690693 SCHEMBL2195376 | 1.00 | AKT1 (1.00) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| Gsk-690693 SCHEMBL29387832 | 1.00 | AKT1 (1.00) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL3487696 | 0.96 | AKT1 (1.00) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL21994179 | 0.93 | AKT1 (0.86) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL10053680 | 0.91 | AKT1 (0.91) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL15446768 | 0.91 | AKT1 (0.83) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL22930437 | 0.91 | AKT1 (0.85) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| Hydrochloric Acid SCHEMBL690160 | 0.90 | AKT1 (0.90) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL18357231 | 0.89 | AKT1 (0.81) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 | |
| SCHEMBL13693040 | 0.89 | AKT1 (0.80) | AKT1ROCK1RPS6KA1AKT2RPS6KA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2241 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743565-A2 | CYTOKINE ENCODING LENTIVIRAL VECTORS AND USES THEREOF FOR MAKING TUMOR INFILTRATING LYMPHOCYTES | Iovance Biotherapeutics, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| CN-122028938-A | Pharmaceutical combination comprising an anti-CD 37 antibody maytansinoid conjugate and a BCL2 inhibitor or PI3K inhibitor | 德彪药业国际股份公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-20260053785-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS INC (US) | 2026-02-26 | — | — | US | claimed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3393477-A1 | COMBINATION OF A CARDIAC STEROID AND AN AKT INHIBITOR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISORDERS | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2018-10-31 | — | — | EP | claimed |
| EP-2367425-B1 | Combination therapy including a taxane and a further therapeutic agent | ABRAXIS BIOSCIENCE LLC (US) | 2018-02-28 | — | — | EP | claimed |
| WO-2017109778-A1 | COMBINATION OF A CARDIAC STEROID AND AN AKT INHIBITOR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISORDERS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2017-06-29 | — | — | WO | claimed |
| US-20150254400-A1 | GROUPING FOR CLASSIFYING GASTRIC CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-10 | — | — | US | claimed |
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | claimed |
| US-7625890-B2 | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors | SMITHKLINE BEECHAM CORP. (US) | 2009-12-01 | — | — | US | claimed |
| WO-2008121685-A1 | METHODS OF USE FOR INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-09 | — | — | WO | claimed |
| EP-1948188-A2 | INHIBITORS OF AKT ACTIVITY | SmithKline Beecham Corporation (US) | 2008-07-30 | — | — | EP | claimed |
| US-20080076763-A1 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC | 2008-03-27 | — | — | US | claimed |
| WO-2007058850-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-24 | — | — | WO | claimed |